Company profile
ACHIEVE LIFE SCIENCES, INC.
NASDAQ:ACHVBiotechnology: In Vitro & In Vivo Diagnostic Substances
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| APATORSEN SODIUM | phase2 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (31)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01497470 | phase1 | completed | 2012-04-01 | 2013-07-01 | Achieve Life Sciences | A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen |
| NCT01630733 | phase3 | completed | 2012-10-24 | 2016-11-17 | Achieve Life Sciences | A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer |
| NCT03303911 | phase1_2 | terminated | 2017-10-06 | 2018-10-05 | Achieve Life Sciences | A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers |
| NCT01454089 | phase2 | completed | 2011-10-01 | 2014-11-01 | Achieve Life Sciences | A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer |
| NCT05206370 | phase3 | completed | 2022-01-20 | 2023-03-21 | Achieve Life Sciences | A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers |
FDA applications (0)
No records yet.